Bioqual Stock

Bioqual Equity

The The Equity of Bioqual (BIOQ) as of Jul 16, 2026 is 36.15 M USD. In the previous year, The Equity was 37.65 M USD — a change of -3.97% (lower).

Equity

36.15 MUSD

YoY

-3.97%

Last updated:

In 2026, Bioqual's equity was 36.15 M USD, a -3.97% increase from the 37.65 M USD equity in the previous year.

Access this data via the Eulerpool API

Bioqual Stock analysis

What does Bioqual do? Bioqual Inc. is an emerging biotechnology company based in Maryland, USA. The company was founded in 1988 with the aim of developing innovative solutions and services for the life sciences and pharmaceutical industry. The founding of Bioqual is closely connected to the emergence of new technologies in the field of biotechnology and genomics research. The company has always been committed to developing innovative products and services that contribute to improving the diagnosis and treatment of diseases, accelerating or facilitating the development of new drugs, and enhancing the quality of animal testing. In its early years, Bioqual primarily focused on the development of diagnostic test systems for animal diseases. In the 1990s, the company expanded its scope to research on infectious diseases and vaccine development. Since 2000, Bioqual has shifted its focus to drug discovery and preclinical studies. Today, Bioqual offers a wide range of products and services in various areas. These include immunological assays, cell culture and microbiology laboratory services, preclinical studies and animal testing services, as well as support in the development of new drugs. An important business model of Bioqual is collaboration with other companies. The company is a key partner for biotech and pharmaceutical companies involved in the development of new drugs and therapies. Bioqual offers preclinical studies and animal testing services to test the effectiveness and safety of new drugs. Partner companies can thus pool their resources and accelerate the testing phase. Bioqual also has its own research and development department and collaborates with academic and medical institutions in the development of new diagnostic and therapeutic methods. Another important area for Bioqual is animal testing services. The company offers specialized animal testing services, including the creation of animal models, conducting studies on the efficacy, pharmacokinetics, and toxicity of substances, as well as regulatory consulting services. In recent years, Bioqual has expanded its presence in the field of diagnostics and treatment of infectious diseases. The company offers serological assays and PCR tests to diagnose infections caused by viruses, bacteria, and parasites. Additionally, Bioqual is involved in the development of vaccines against a variety of infectious diseases, including HIV, Hepatitis C, Zika, and West Nile Virus. The products and services of Bioqual are applied in various areas of life sciences and medicine. They are utilized by pharmaceutical and biotech companies, government agencies, academic institutions, and medical laboratories. Bioqual has shown strong growth in recent years. The company continuously invests in research and development of new products and services to meet the needs of its customers. The company also has a strong presence in various global markets, particularly in Europe, Asia, and South America. Bioqual has established a reputation as an innovative and reliable company in the biotechnology and pharmaceutical industry. With its wide range of products and services and close collaboration with other companies, Bioqual positions itself as a key partner in the development of new diagnostic and therapeutic methods, as well as the exploration of infectious diseases and new drugs. Bioqual is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Bioqual's Equity

Bioqual's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bioqual's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bioqual's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bioqual's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bioqual’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bioqual stock

The Equity of Bioqual is 36.15 M USD in 2026.

Access this data via the Eulerpool API

Balance Sheet — Bioqual

All Key Metrics — Bioqual